Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar Fiskhus (72.87) Submitted: 2/4/2011 8:21:30 PM : Outperform Start Price: $3.05 DVAX Score: +18.84

MB7 Z3

Featured Broker Partners


Advertisement